Cytokinetics (CYTK) Competitors

$77.22 +2.41 (+3.22%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$77.00 -0.22 (-0.28%)

As of 04:23 AM Eastern

CYTK vs. RVMD, INSM, BNTX, ROIV, and MRNA

Should you buy Cytokinetics stock or one of its competitors? MarketBeat compares Cytokinetics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cytokinetics include Revolution Medicines (RVMD), Insmed (INSM), BioNTech (BNTX), Roivant Sciences (ROIV), and Moderna (MRNA). These companies are all part of the "pharmaceutical products" industry.

How does Cytokinetics compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Cytokinetics has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,752.78	-$1.13B	-$7.07	N/A
Cytokinetics	$88.04M	109.14	-$784.96M	-$6.84	N/A

Revolution Medicines has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Revolution Medicines has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Cytokinetics	-784.02%	N/A	-52.86%

Revolution Medicines currently has a consensus price target of $103.88, indicating a potential downside of 30.72%. Cytokinetics has a consensus price target of $98.55, indicating a potential upside of 27.62%. Given Cytokinetics' higher possible upside, analysts clearly believe Cytokinetics is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	3.10
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Cytokinetics had 11 more articles in the media than Revolution Medicines. MarketBeat recorded 31 mentions for Cytokinetics and 20 mentions for Revolution Medicines. Cytokinetics' average media sentiment score of 0.46 beat Revolution Medicines' score of 0.19 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytokinetics	7 Very Positive mention(s)	0 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

94.3% of Revolution Medicines shares are owned by institutional investors. 8.2% of Revolution Medicines shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Cytokinetics beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to Insmed?

Insmed (NASDAQ:INSM) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Cytokinetics has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	42.17	-$1.28B	-$5.75	N/A
Cytokinetics	$88.04M	109.14	-$784.96M	-$6.84	N/A

Insmed has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Insmed has a net margin of -144.44% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Cytokinetics	-784.02%	N/A	-52.86%

Insmed currently has a consensus price target of $210.95, indicating a potential upside of 78.79%. Cytokinetics has a consensus price target of $98.55, indicating a potential upside of 27.62%. Given Insmed's stronger consensus rating and higher possible upside, research analysts clearly believe Insmed is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Insmed had 13 more articles in the media than Cytokinetics. MarketBeat recorded 44 mentions for Insmed and 31 mentions for Cytokinetics. Insmed's average media sentiment score of 0.56 beat Cytokinetics' score of 0.46 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	15 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Cytokinetics	7 Very Positive mention(s)	0 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Insmed beats Cytokinetics on 11 of the 15 factors compared between the two stocks.

How does Cytokinetics compare to BioNTech?

Cytokinetics (NASDAQ:CYTK) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

BioNTech has a net margin of -44.39% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
BioNTech	-44.39%	-5.30%	-4.62%

Cytokinetics has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

In the previous week, Cytokinetics had 18 more articles in the media than BioNTech. MarketBeat recorded 31 mentions for Cytokinetics and 13 mentions for BioNTech. Cytokinetics' average media sentiment score of 0.46 beat BioNTech's score of 0.39 indicating that Cytokinetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	7 Very Positive mention(s)	0 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cytokinetics presently has a consensus price target of $98.55, indicating a potential upside of 27.62%. BioNTech has a consensus price target of $130.60, indicating a potential upside of 41.60%. Given BioNTech's higher probable upside, analysts clearly believe BioNTech is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.82
BioNTech	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Cytokinetics has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	109.14	-$784.96M	-$6.84	N/A
BioNTech	$3.25B	7.18	-$1.29B	-$5.88	N/A

15.5% of BioNTech shares are held by institutional investors. 2.6% of Cytokinetics shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Cytokinetics and BioNTech tied by winning 8 of the 16 factors compared between the two stocks.

How does Cytokinetics compare to Roivant Sciences?

Cytokinetics (NASDAQ:CYTK) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

64.8% of Roivant Sciences shares are held by institutional investors. 2.6% of Cytokinetics shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cytokinetics has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

Cytokinetics has a net margin of -784.02% compared to Roivant Sciences' net margin of -6,079.94%. Cytokinetics' return on equity of 0.00% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Roivant Sciences	-6,079.94%	-19.04%	-18.15%

In the previous week, Cytokinetics had 24 more articles in the media than Roivant Sciences. MarketBeat recorded 31 mentions for Cytokinetics and 7 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.16 beat Cytokinetics' score of 0.46 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	7 Very Positive mention(s)	0 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytokinetics presently has a consensus price target of $98.55, indicating a potential upside of 27.62%. Roivant Sciences has a consensus price target of $30.55, indicating a potential upside of 4.55%. Given Cytokinetics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cytokinetics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.82
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Roivant Sciences has lower revenue, but higher earnings than Cytokinetics. Roivant Sciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	109.14	-$784.96M	-$6.84	N/A
Roivant Sciences	$29.05M	719.89	-$171.98M	-$1.17	N/A

Summary

Cytokinetics beats Roivant Sciences on 9 of the 17 factors compared between the two stocks.

How does Cytokinetics compare to Moderna?

Cytokinetics (NASDAQ:CYTK) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

75.3% of Moderna shares are held by institutional investors. 2.6% of Cytokinetics shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cytokinetics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Moderna has a net margin of -143.55% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Moderna	-143.55%	-26.64%	-19.32%

In the previous week, Moderna had 11 more articles in the media than Cytokinetics. MarketBeat recorded 42 mentions for Moderna and 31 mentions for Cytokinetics. Moderna's average media sentiment score of 0.62 beat Cytokinetics' score of 0.46 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	7 Very Positive mention(s)	0 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	21 Very Positive mention(s)	7 Positive mention(s)	6 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive

Cytokinetics presently has a consensus price target of $98.55, indicating a potential upside of 27.62%. Moderna has a consensus price target of $35.73, indicating a potential downside of 29.13%. Given Cytokinetics' stronger consensus rating and higher probable upside, research analysts clearly believe Cytokinetics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.82
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

Cytokinetics has higher earnings, but lower revenue than Moderna. Cytokinetics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	109.14	-$784.96M	-$6.84	N/A
Moderna	$1.94B	10.29	-$2.82B	-$8.15	N/A

Summary

Moderna beats Cytokinetics on 9 of the 17 factors compared between the two stocks.

Get Cytokinetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYTK vs. The Competition

Export

Metric	Cytokinetics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.31B	$3.42B	$6.30B	$12.20B
Dividend Yield	N/A	2.30%	2.79%	5.30%
P/E Ratio	-11.29	18.67	21.03	25.58
Price / Sales	109.14	301.13	552.98	78.84
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	-11.63	6.75	9.82	6.66
Net Income	-$784.96M	$24.11M	$3.55B	$333.63M
7 Day Performance	3.94%	-0.53%	-0.53%	-0.11%
1 Month Performance	16.38%	0.34%	1.20%	3.94%
1 Year Performance	157.40%	78.62%	41.23%	36.07%

Cytokinetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYTK Cytokinetics	2.8574 of 5 stars	$77.22 +3.2%	$98.55 +27.6%	+152.3%	$9.31B	$88.04M	N/A	250	Trending News Analyst Forecast Options Volume Analyst Revision
RVMD Revolution Medicines	2.232 of 5 stars	$147.90 +6.0%	$78.94 -46.6%	+275.3%	$29.65B	$11.58M	N/A	250	Analyst Revision
INSM Insmed	3.1505 of 5 stars	$140.01 +5.1%	$213.23 +52.3%	+79.6%	$28.76B	$606.42M	N/A	1,664	Trending News Earnings Report Analyst Forecast Analyst Revision
BNTX BioNTech	3.8 of 5 stars	$99.35 +1.9%	$133.13 +34.0%	-2.4%	$24.67B	$3.25B	N/A	7,807	Analyst Forecast Buyback Announcement
ROIV Roivant Sciences	2.4624 of 5 stars	$28.36 +1.9%	$30.55 +7.7%	+171.6%	$19.92B	$29.05M	N/A	860	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYTK) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytokinetics (CYTK) Competitors

CYTK vs. RVMD, INSM, BNTX, ROIV, and MRNA

How does Cytokinetics compare to Revolution Medicines?

Summary

How does Cytokinetics compare to Insmed?

Summary

How does Cytokinetics compare to BioNTech?

Summary

How does Cytokinetics compare to Roivant Sciences?

Summary

How does Cytokinetics compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK vs. The Competition

Cytokinetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytokinetics (CYTK) Competitors

CYTK vs. RVMD, INSM, BNTX, ROIV, and MRNA

How does Cytokinetics compare to Revolution Medicines?

Which has better earnings & valuation, RVMD or CYTK?

Which has more volatility and risk, RVMD or CYTK?

Is RVMD or CYTK more profitable?

Do analysts prefer RVMD or CYTK?

Does the media favor RVMD or CYTK?

Do institutionals & insiders believe in RVMD or CYTK?

Summary

How does Cytokinetics compare to Insmed?

Which has better earnings & valuation, INSM or CYTK?

Which has more volatility & risk, INSM or CYTK?

Is INSM or CYTK more profitable?

Do analysts prefer INSM or CYTK?

Does the media favor INSM or CYTK?

Summary

How does Cytokinetics compare to BioNTech?

Is CYTK or BNTX more profitable?

Which has more volatility and risk, CYTK or BNTX?

Does the media refer more to CYTK or BNTX?

Do analysts recommend CYTK or BNTX?

Which has stronger valuation & earnings, CYTK or BNTX?

Do insiders and institutionals have more ownership in CYTK or BNTX?

Summary

How does Cytokinetics compare to Roivant Sciences?

Do insiders and institutionals have more ownership in CYTK or ROIV?

Which has more volatility and risk, CYTK or ROIV?

Is CYTK or ROIV more profitable?

Does the media refer more to CYTK or ROIV?

Do analysts recommend CYTK or ROIV?

Which has stronger valuation & earnings, CYTK or ROIV?

Summary

How does Cytokinetics compare to Moderna?

Do institutionals and insiders have more ownership in CYTK or MRNA?

Which has more risk and volatility, CYTK or MRNA?

Is CYTK or MRNA more profitable?

Does the media prefer CYTK or MRNA?

Do analysts prefer CYTK or MRNA?

Which has higher valuation and earnings, CYTK or MRNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYTK vs. The Competition

Cytokinetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools